chufangao/CTO huggingface dataset:
Clinical trial NCT04205890: Intravenous Ketamine Effects on Functional Neuroanatomy
Official title: Intravenous Ketamine Effects on Functional Neuroanatomy
Sponsor: Neurological Associates of West Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor is no longer interested in funding the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-02
Primary completion date: 2020-05-28
Completion date: 2020-05-28
Plan to share individual participant data: NO
IPD sharing description: Data from this study will not be made publicly available due to ethical and privacy concerns. Anonymized data will be available upon reasonable request from any qualified investigator.
Clinical trial NCT05394558: AsiDNA Children, Adolescents and Young Adults
Official title: A Phase Ib/II Study on AsiDNA in Association With Re-irradiation in Children, Adolescents and Young Adults With High-grade Glioma
Acronym: AsiDNA
Sponsor: Institut Curie (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: IDMC recommendations
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-27
Primary completion date: 2023-09-20
Completion date: 2023-09-20
Plan to share individual participant data: YES
IPD sharing description: Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.
IPD time frame: Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months
IPD access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).
Clinical trial NCT02623426: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
Official title: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
Acronym: MERIT
Sponsor: JHSPH Center for Clinical Trials (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 194.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-09
Primary completion date: 2021-10-27
Completion date: 2022-02-02
Baseline population: Randomized participants had 1 or both eyes with macular edema, defined as the presence of central subfield macular thickness greater than the normal range for the OCT machine being used
Clinical trial NCT04341935: Effects of DPP4 Inhibition on COVID-19
Official title: Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Logistical challenges amid COVID-19 pandemic and lack of financial support
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-30
Primary completion date: 2021-12-30
Completion date: 2021-12-30
Plan to share individual participant data: NO
Clinical trial NCT04957290: A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Official title: A Phase 1b/2a Multicenter Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Sponsor: Noxopharm Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Slow Recruitment
Enrollment: 21.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-10-25
Primary completion date: 2023-05-10
Completion date: 2023-06-07
Baseline population: Study terminated early during part 1- cohort 3.
Limitations and caveats: Dose escalation progressed through the first 3 planned dose levels before the Sponsor decided to terminate the study for business reasons; the decision was not based on any safety concerns with NOX66.~Due to early termination, none of the efficacy parameters were able to be measured therefore only safety outcomes are available.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04643886: A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
Official title: A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
Sponsor: Gemini Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: no further benefit
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-30
Primary completion date: 2022-02-18
Completion date: 2022-03-21
Plan to share individual participant data: NO
Clinical trial NCT04479904: A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
Official title: A Single-Arm, Open-Label, Multi-Center, Phase II Study of Famitinib Malate to Treat Intrahepatic Cholangiocarcinoma Patients With FGFR2(Fibroblast Growth Factor Receptor2) Genetic Aberrations Who Failed First-Line Therapy
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: It is difficult to screening subject
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-10
Primary completion date: 2021-12-10
Completion date: 2022-02-10
Clinical trial NCT03941496: Azacytidine During Anti-tuberculosis Therapy
Official title: Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy
Acronym: AZA
Sponsor: Baylor College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-10-31
Primary completion date: 2023-05-31
Completion date: 2023-05-31
Plan to share individual participant data: NO
Clinical trial NCT04704050: Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
Official title: Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence Post Ablation: The EDORA Trial
Acronym: EDORA
Sponsor: Tulane University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Sponsor withdrew funding
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-15
Primary completion date: 2022-12-20
Completion date: 2022-12-20
Plan to share individual participant data: NO
Clinical trial NCT04519424: CSL324 in COVID-19
Official title: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Coronavirus Disease 2019 (COVID-19)
Sponsor: CSL Behring (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to business reasons, not safety issues.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2021-04-30
Completion date: 2021-05-31
Plan to share individual participant data: YES
IPD sharing description: CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.~Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.~If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
IPD time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
IPD access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.~An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.~The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
Clinical trial NCT04610658: Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Official title: Activity and Enhancement of Immune Checkpoint Inhibition With Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: DLTs
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-23
Primary completion date: 2023-03-24
Completion date: 2023-03-24
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03800875: Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting
Official title: A Randomized, Controlled, Crossover Trial to Assess a Dual-hormone (Insulin-pramlintide) Closed-loop Delivery Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes
Acronym: Dual
Sponsor: McGill University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-08
Primary completion date: 2020-09-19
Completion date: 2020-09-19
Plan to share individual participant data: YES
IPD sharing description: The raw data (i.e., insulin delivery, glucose levels, individual participant data) and informed consent form could be shared by the corresponding author, ahmad.haidar@mcgill.ca, upon reasonable request for academic purposes, subject to Material Transfer Agreement and approval of McGill University Health Center's Research Ethics Board. All data shared will be de-identified. The study protocol will be available with publication.
Clinical trial NCT03982537: Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Official title: Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome and on the Degree of Mucositis Developed in Response to Concurrent Chemotherapy and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Concept is withdrawn and a different concept will be submitted the near future.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-18
Primary completion date: 2020-06-18
Completion date: 2020-06-18
Plan to share individual participant data: NO
Clinical trial NCT04148261: Epinephrine and Cortisol in Depression
Official title: The Effects of Epinephrine and Cortisol on Emotion in Depression
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Principal Investigator left lab before study start
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-12-31
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT04780269: Foley Catheter Versus PGE2 for Labor Induction at Term: a Pilot Study
Official title: Foley Catheter Versus Prostaglandin E2 Vaginal Suppository for Labor Induction at Term: a Pilot Study
Sponsor: Guangzhou Women and Children's Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: understaffed
Enrollment: 200.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2023-12-31
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT05172570: Gabapentin Dosages for Postoperative Analgesia Following Open Thoracotomy
Official title: Randomized Prospective Study Comparing Variable Gabapentin Dosages for Postoperative Analgesia Following Open Thoracotomy
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study terminated to to shortage if study supplies for epidurals and most enrolled has study deviations due to not receiving correct post study drug assignments.
Enrollment: 20.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-04-06
Primary completion date: 2022-02-25
Completion date: 2022-03-02
Baseline population: Baseline demographics
Plan to share individual participant data: NO
Clinical trial NCT03902080: Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Official title: A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Sponsor: Urovant Sciences GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1105.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-26
Primary completion date: 2023-06-15
Completion date: 2023-06-15
Baseline population: Full Analysis Set consists of all randomized participants who took at least 1 dose of double-blind study treatment and had at least 1 evaluable change from Baseline mictruition
Plan to share individual participant data: YES
IPD sharing description: Urovant is committed to sharing patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Data requests will be reviewed and approved on the basis of scientific merit. All data provided will be anonymized according to applicable laws and regulations.
IPD time frame: The data will be made available within 24 months after study completion and will be accessible for a time frame appropriate for the approved proposal.
IPD access criteria: Access to these clinical trial data can be requested by emailing medinfo@urovant.com and will be provided following Urovant review and approval of a research proposal and execution of a Data Sharing Agreement (DSA).
Clinical trial NCT03534102: Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption
Official title: Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Due to limitations caused by COVID, enrollment targets could not be met.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-06-06
Primary completion date: 2023-09-01
Completion date: 2024-09-01
Plan to share individual participant data: NO
Clinical trial NCT04221087: Steroid Use in Non-RSV Bronchiolitis
Official title: Dexamethasone Use for the Treatment of Non-RSV Bronchiolitis
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID19-pandemic, RSV surge
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-03
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT04447729: A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
Official title: A Multicenter, Open-label Pilot Study of the Efficacy and Safety of Fremanezumab for Treatment of Female Patients With Interstitial Cystitis-Bladder Pain Syndrome
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawn due to logistic reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-15
Primary completion date: 2022-02-10
Completion date: 2022-02-10
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
Clinical trial NCT04130919: Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
Official title: A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects With Moderately to Severely Active Ulcerative Colitis
Acronym: Falcon
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor terminated the study since a new molecular entity was able to achieve greater target coverage
Enrollment: 19.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-12-20
Primary completion date: 2021-02-25
Completion date: 2021-12-14
Baseline population: Safety Analysis Set included all participants who received at least 1 dose of study drug.
Limitations and caveats: Gilead made the decision to discontinue the development of tilpisertib since a new molecular entity was able to achieve greater target coverage. The decision was not due to any safety concerns. Since only 19 participants were enrolled, none of the planned statistical analyses were performed. During the coronavirus disease 2019 (COVID-19) pandemic, there were changes to protocol visits and procedures where necessary to mitigate the impact of the pandemic to the study.
Plan to share individual participant data: NO
Clinical trial NCT03093155: Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Official title: A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 78.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-03
Primary completion date: 2022-12-29
Completion date: 2022-12-29
Baseline population: Only those that remained on study are included in the baseline characteristics.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05048719: A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Official title: A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 383.0 (ACTUAL)
Number of arms: 9.0
Start date: 2021-09-15
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Baseline population: All randomized participants who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04330872: An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.
Official title: An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke. Non-randomized Interventional Controlled Clinical Trial.
Acronym: ECASIS
Sponsor: Hamad Medical Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-26
Primary completion date: 2020-01-04
Completion date: 2020-03-04
Clinical trial NCT02516670: Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Official title: A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: insufficient clinical response per DSMB
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-20
Primary completion date: 2021-07-31
Completion date: 2021-10-14
Clinical trial NCT05156827: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
Official title: A Phase 2 Double-blind, Randomized, Multi-center, Parallel-group Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Patients With Acute Ischemic Stroke
Sponsor: TrueBinding, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Business decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-26
Primary completion date: 2023-12-18
Completion date: 2023-12-18
Plan to share individual participant data: NO
Clinical trial NCT05039359: Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm
Acronym: RESTORE-1
Sponsor: InCarda Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Limited efficacy upon blinded review
Enrollment: 54.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-26
Primary completion date: 2023-05-22
Completion date: 2023-05-22
Plan to share individual participant data: NO
Clinical trial NCT03544073: GnRH Agonist at Embryo Transfer: IVF Outcomes
Official title: Does a GnRH Agonist Given at Embryo Transfer Improve Clinical Pregnancy and Live Birth Rates of Women Undergoing In-Vitro Fertilization?
Acronym: GRAET
Sponsor: Maimonides Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The investigators were not able to get grant funding for this study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-15
Primary completion date: 2020-06-30
Completion date: 2021-06-30
Clinical trial NCT04557280: A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects
Official title: A Randomized, Open-label, 3-period Cross-over Study to Assess the Pharmacokinetics of Selatogrel (ACT-246475) in Healthy Subjects After Subcutaneous Administration by Syringe and Auto-injector
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-06
Primary completion date: 2020-12-19
Completion date: 2020-12-19
Plan to share individual participant data: NO
Clinical trial NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
Official title: P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Sponsor: Veru Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Decided to halt and will potentially reopen in the future.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-03-15
Primary completion date: 2024-03-30
Completion date: 2024-05-26
Plan to share individual participant data: UNDECIDED